Battling global burden of stroke requires solid data and policies

"Data is really important. It can provide an impetus of action."

Amanda Thrift, BSc(Hons), PhD, PGDipBiostat

Stroke is a global health threat that affects populations disproportionately, but that disparity can be addressed with more data and more government interventions, researchers said Wednesday.

"In middle and low-income countries, the volume of stroke is twice as worse compared to high-income countries," said Mayowa Owalabi, MBBS, MSc, DTM, MWAPE, MFMCP, FAAN, from the College of Medicine at the University of Ibaden in Nigeria, who moderated the session called "Tackling stroke in low- and middle-income countries — placing proof in pragmatism."

World Health Organization data indicates that although stroke incidence, prevalence, mortality and disability-adjusted life-years rates declined from 1990 to 2013, the absolute number of people affected by stroke has increased across the globe in men and women of all ages.

"Strokes occur at younger ages in low- and middle-income countries, when people are still working age," said presenter Amanda Thrift, BSc(Hons), PhD, PGDipBiostat from Melbourne, Australia.

Yet, in many low- and middle-income countries (LMICs), high-quality incidence and mortality data gaps exist to indicate the true burden of disease. Without solid epidemiological evidence, it’s difficult to drive research and persuade governments to establish acute and comprehensive stroke centers as well as patient education programs and policies that reduce stroke risk, Thrift said.

"Data is really important," she said. "It can provide an impetus of action."

To address these gaps in incidence and mortality data, the Lancet Commission on Stroke in LMICs is relying on hospital-based registries to help identify populations at risk for stroke.

Meanwhile, some LMICs are making

Pioglitazone may be effective in preventing secondary stroke

Pioglitazone, a drug that appears to act on the same biological pathways as lifestyle interventions, can be similarly effective in secondary stroke prevention, a researcher said Wednesday.

"Pioglitazone is the only diabetes drug shown to prevent vascular disease," Walter N. Kernan, MD, said during an ISC seminar on diabetes and stroke. "It is a very useful drug for secondary stroke prevention."

Kernan, professor of medicine at Yale School of Medicine, is the principle investigator of IRIS (Insulin Resistance Intervention after Stroke).

Pioglitazone improves glucose metabolism, fat metabolism and endothelial function while reducing inflammation. While it has fallen out of favor due to a black box warning for congestive heart failure and a subsequent warning for increased bone fracture risk, it’s the only drug shown to prevent diabetes. It also reduces the risk of stroke or myocardial infarction by 34 percent.

Download the Mobile Meeting Guide app from the Apple App Store or Google Play.
JOIN US TODAY!

CRYPTOGENIC STROKE — THE MISSING LINQ

Thursday, January 25
Expert Theater

12:10–12:40 p.m.
Exhibit Hall Floor
Booth #401

This event is not part of the official International Stroke Conference 2018 as planned by the International Stroke Conference Program Committee.

PROGRAM FACULTY

Robert Felberg, M.D.
Medical Director
Overlook Hospital
Summit, NJ
‘Crossfire Debates’ return as part of Closing Main Event

C
ontroversy surrounding anticoagulation therapy, hemicraniectomy and cardiac ambulatory monitoring will be hashed out during “Crossfire Debates” in the first hour of Friday’s Closing Main Event at 10:30 a.m. in Hall K.

“These are topics that clinicians are struggling with every day,” said Bruce Ovbiagele, MD, ISC 2018 program chair. “The debates present the opportunity for the audience to hear both sides of fundamental clinical issues by speakers chosen for their expertise and opinions.

“We chose speakers based on either their published opinion or on studies they’ve invested time and effort in and who would have a stronger perspective on the issue.”

The debates were so popular after being introduced last year that the program committee brought them back this year, Ovbiagele said.

“The original idea was for us to have ‘Crossfire’ one year and alternate with ‘Next Best Thing,’” he said. “But ‘Crossfire’ was so popular, not just in terms of the audience participation, but also lots of anecdotal comments and emails from people saying they loved it. That’s why we decided to do it two years in a row.”

The debates cover three topics, with each session lasting about 20 minutes:

• “Anticoagulation Therapy Should Not Be Restarted in Patients With Anticoagulation-Related Lobar Intracerebral Hemorrhage” will be moderated by Joseph P. Broderick, MD, professor of neurology and director at the University of Cincinnati Gardner Neuroscience Institute.

“The big issue is trying to balance the need to avoid the repeat of the lobar hemorrhage with the need to also prevent ischemic stroke from occurring,” Ovbiagele said.

Some clinicians wait six weeks before restarting anticoagulation and others three months. Others don’t restart it to avoid the risk of another lobar hemorrhage, managing blood pressure instead. Some decide to put patients on antiplatelet therapy to strike a middle ground.

“The evidence for doing any of these things is not very strong,” he said. “There have been some observational data that has suggested that actually stopping these patients on anticoagulation is beneficial because you prevent them from having ischemic strokes down the line even though they might be at increased risk in lobar hemorrhage. But you’re really able to offset the risk of an ischemic stroke by stopping them on anticoagulation.”

• “Hemicraniectomy Versus Not in Patients Over 60” will be moderated by William J. Mack, MD, associate professor of neurological surgery in the Keck School of Medicine of the University of Southern California in Los Angeles.

Hemicraniectomy is performed to reduce intracranial pressure caused by middle cerebral artery ischemic strokes.

“We know, based on three clinical trials, that hemicraniectomy works in patients that are less than 60,” Ovbiagele said. “However, above the age of 60, the data are not so clear.

‘The age distinction was made owing to the fact that brains shrink with age. For a time with older patients, we said, ‘Because they have more space to expand, maybe we didn’t have to do this surgical procedure to relieve pressure in their brains.’ So we would restrict it to the younger patients. Since that time, we’ve had one trial that has suggested that this procedure might be beneficial in older patients. But the results were not overwhelming like they were in the younger patients.”

Werner Hacke, MD, PhD, professor and chair of neurology at the University of Heidelberg in Germany, will argue on the pro side. Ashfaq Shuaib, MD, see DEBATES, page 7

Session to explore global stance on hypertension and stroke risk

SC 2018 attendees can explore a global view of hypertension and stroke risk in a Friday morning session.

“The Global Impact of Hypertension and Stroke: A Call to Action,” held at 8:45-10:15 a.m. in Room 408, is on the heels of the recent release of the 2017 Guidelines for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults.

“We’re known for many years that the No. 1 factor associated with stroke is high blood pressure,” said Daniel T. Lackland, DrPH, FACE, FAHA, president of the World Hypertension League.

As new guidelines and ideas are introduced regarding blood pressure and stroke risk, it’s an opportunity to recognize the global impact of hypertension and stroke beyond North America and Europe.

In the United States, one in 20 deaths are due to stroke annually, making it the fifth leading cause of mortality. But in other major populations in countries and regions such as Brazil, China, India and Sub-Saharan Africa, stroke is the leading cause of death.

The most common risk factor globally, hypertension is responsible for 174 million disability-adjusted lives (DALY’s) every year. The Global Burden of Disease Study 2013 indicated that 17.3 million people die from cardiovascular diseases annually, accounting for nearly one third of total deaths worldwide. About 53 percent of DALY’s are related to ischemic heart disease, the most common type of cardiovascular disease and the leading cause of death in the world.

ISC 2018 will provide a forum for the American Heart Association/American Stroke Association, the World Hypertension League and the World Stroke Organization to discuss primary and secondary prevention strategies from around the world.

As a framework for discussion, the moderators will present:

“How do we take this new evidence and apply it globally?”

The session will include a presentation on hypertension treatment in diabetic patients to lower stroke risks by Philip B. Gorelick, MD, MPH, executive medical director at Mercy Health Hauenstein Neuroscience in Grand Rapids, Michigan.

Speakers will address practical prevention strategies for global populations, including those in the United States, with a focus on hypertension, page 10

Thursday, January 25, 2018 | Stroke News

Hearty Humor by Jonny Hawkins

“Forgot therim, I’m on a low-blubber diet.”

Thursday, January 25, 2018

StrokeNews is produced for the American Heart Association/American Stroke Association’s International Stroke Conference by Accord Integrated Media, LLC. atascmedicine.com. Past advertisements are not reviewed by the AHA for scientific accuracy.

Yvette Ballyntyne, MA
Senior Manager, International Stroke Conference
Heather Stiles
Manager, Corporate Sponsored Projects
Nicole Cappellini
Editorial Manager, Content and News
Anna Lexander MPH, RN, CCRN
Science and Medicine Advisor
Phaidra Kawonga, PhD
Science and Medicine Advisor
Omary Fakih, MD, MPH, Science and Medicine Advisor

©2018 by the American Heart Association/American Stroke Association, 7272 Greenville Avenue, Dallas, TX 75231-1899 | 1-888-4-STROKE | strokeassociation.org

When you read this issue of Stroke News, please share with colleagues or deposit it in an unprinted paper recycling bin.

ISC 2019 AWARD NOMINATIONS

AHA Members: Submit your nominations for the ISC 2019 Feinberg, Sherman, Wills and Research Mentor awards.

Nomination Period Opened: Wednesday, Jan. 24, 2018
Nomination Period Closes: Wednesday, June 27, 2018

Go to strokeconference.org/awards for more information.

PRODUCTS & SHOWCASES

PAID ADVERTISEMENT

The Stroke Association of Southern California

“The Empowerment Stage of Stroke Recovery” is a new stage of treatment that follows acute and subacute care, and provides education, guidance, support and hope that the “chronic stage” does not. Please tell patients about empowerment after stroke.

For information, contact Booth 141, strokesocal.org and (310) 575-1699

strokeconference.org
Highlights FROM THE 2018 GUIDELINES FOR THE EARLY MANAGEMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE

The 2018 Acute Ischemic Stroke (AIS) Guideline provides an up-to-date, comprehensive set of recommendations for clinicians caring for adult patients with AIS. Working jointly with the American Heart Association and American Stroke Association, a panel of 19 scientists and health experts analyzed more than 400 studies to develop this Guideline.

Stroke is the No. 2 cause of death worldwide and the No. 5 cause of death in the United States. In fact, more than 690,000 Americans per year have an AIS due to a blood clot, and more than one third of these strokes result from a large-vessel clot, which increases the chance of severe brain damage and death. Time lost is brain lost. Thus, every minute that treatment is delayed reduces the chance of severe brain damage and may mean the difference between survival and death (Fig. 1). The updated Guideline recommends brain imaging—typically a noncontrast computerized tomography (CT) scan—within 20 minutes after a patient with suspected stroke arrives at the hospital. A hospital’s goal should be to achieve this in at least 50% of patients who may be eligible for IV alteplase or mechanical thrombectomy.

Key Recommendations in the 2018 AIS Guideline

To help improve care for stroke patients, the AIS Guideline has been updated to include new and revised recommendations about pre-hospital care; urgent and emergency evaluation and treatment with intravenous and intra-arterial therapies; and in-hospital management, including appropriately instituting secondary prevention measures within the first 2 weeks. The Guideline emphasizes that effective stroke treatment and measures to prevent stroke recurrence should begin as quickly as possible, and it highlights the need for public stroke education programs that are tailored for diverse races, ages, and genders. The Guideline also expands patient eligibility criteria for stroke treatments, including intravenous (IV) alteplase and mechanical thrombectomy:

- **Alteplase**, a clot-breaking drug that is administered via IV, remains an important initial AIS treatment in the updated Guideline, including in the recommendation to evaluate patients up to 4.5 hours after the onset of stroke and to use telestroke conferencing when stroke specialists are not available on-site (refer to Table 6 in the 2018 AIS Guideline for more information about alteplase eligibility). Additional recommendations include faster door-to-needle times for IV alteplase treatment and careful evaluation of AIS patients, including those with mild stroke, to determine whether the potential benefits of alteplase outweigh the risks. Alteplase is covered in greater detail later in this publication.

- **Mechanical thrombectomy**, a procedure in which a doctor inserts a catheter into a large blood vessel inside the head and uses a device to pull out a clot, has proven effective in lowering disability from stroke. The updated Guideline increases the recommended time frame for mechanical thrombectomy in select patients from 6 hours to 24 hours after the stroke begins. Unchanged from the previous Guideline is the recommendation that the mechanical thrombectomy be performed at an experienced stroke center; however, patients or families who suspect stroke should call 9-1-1 and let the doctors and emergency responders determine the best hospital for care. Mechanical thrombectomy is also discussed later in this publication.

New Recommendations for Healthcare Providers

**Systems of Care**

The updated Guideline recommends developing regional systems of stroke care with facilities that can:

- Provide initial emergency care, including administration of IV alteplase
- Perform more advanced care, such as endovascular treatment with comprehensive periprocedural care
- Facilitate rapid transport to advanced centers when appropriate
- Participate in a stroke data repository to improve adherence to treatment guidelines, continuous quality improvement, and patient outcomes

In addition, the Guideline recommends that these systems of care establish door-to-needle times within 60 minutes in 50% or more of stroke patients who are treated with IV alteplase, with secondary door-to-needle times within 45 minutes considered reasonable.

**Telestroke/Teleradiology**

For hospitals that do not have neurologists on call, the updated Guideline recommends telestroke evaluations to determine a patient’s eligibility for IV alteplase; stroke specialists who participate in these video conferences can provide alteplase treatment guidance that’s as effective as treatment given at stroke centers. Telestroke may also be reasonable for triaging patients with AIS who may be eligible for transfer to receive mechanical thrombectomy.

**Brain Imaging**

The updated Guideline recommends brain imaging—typically a noncontrast computerized tomography (CT) scan—within 20 minutes after a patient with suspected stroke arrives at the hospital. A hospital’s goal should be to achieve this in at least 50% of patients who may be eligible for IV alteplase or mechanical thrombectomy.
Alteplase

Studies and experience have shown the benefits of using IV alteplase for treating AIS; therefore, all patients who are eligible for alteplase should receive it, even patients being considered for mechanical thrombectomy. Exclusion and inclusion criteria for alteplase therapy have evolved over the years, so it’s important to review the updated criteria in Table 6 of the 2018 AIS Guideline.

The goal for IV alteplase treatment is unchanged—treat as soon as possible up to 4.5 hours after symptom onset. Treatment with alteplase may also benefit those with mild symptoms and adults with AIS who have sickle cell disease.

Mechanical Thrombectomy

The updated Guideline recommends that AIS patients should receive mechanical thrombectomy if they:

- Have a prestroke modified Rankin Scale score of 0 to 1
- Have causative occlusion of the internal carotid artery or middle cerebral artery segment 1 (MI)
- Are age 18 years or older
- Have a National Institutes of Health Stroke Scale score of 6 or greater
- Have an Alberta Stroke Program Early CT score of 6 or greater
- Can receive treatment (groin puncture) within 6 hours of symptom onset

In addition, mechanical thrombectomy is recommended for select patients who:

- Are within 6 to 24 hours of symptom onset
- Have large-vessel occlusion in the anterior circulation
- Meet other DAWN³ or DEFUSE-3² eligibility criteria

Revascularization

The updated Guideline recommends performing noninvasive imaging of the cervical vessels within 24 hours of admission for patients who have mild or nondisabling AIS in the carotid territory and are candidates for carotid endarterectomy or stenting to prevent subsequent stroke. If there are no contraindications, it is reasonable to perform the revascularization procedure between 48 hours and 7 days of the index event.

Antiplatelet and Anticoagulant Therapy

Aspirin is recommended for AIS patients within 24 to 48 hours after symptom onset, as follows:

For AIS patients who

<table>
<thead>
<tr>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Were treated with IV alteplase</td>
</tr>
</tbody>
</table>
| Were treated with IV alteplase and have comorbid conditions | Earlier aspirin treatment might be considered if:
  - It is known to provide substantial benefit in the absence of IV alteplase, or
  - Withholding such treatment is known to cause substantial risk |
| Have mild stroke symptoms and were not treated with IV alteplase | Dual antiplatelet therapy with aspirin and clopidogrel started within 24 hours and continued for 21 days may prevent secondary stroke. |

It is reasonable that patients with atrial fibrillation start oral anticoagulants within 4 to 14 days of the AIS event. Immobile patients with AIS should receive intermittent pneumatic compression to prevent venous thromboembolism, as such deep vein thrombosis.

It is unclear if prophylactic-dose subcutaneous heparin (unfractionated heparin or low-molecular weight heparin) is beneficial in these patients.

Blood Pressure Management

The updated Guideline recommends the following to manage blood pressure in AIS patients:

For AIS patients who

<table>
<thead>
<tr>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Have comorbid conditions requiring blood pressure reduction</td>
</tr>
<tr>
<td>Did not receive IV alteplase or endovascular treatment</td>
</tr>
<tr>
<td>Do not have a comorbid condition that requires acute antihypertensive treatment</td>
</tr>
<tr>
<td>Receive IV alteplase</td>
</tr>
<tr>
<td>Are undergoing mechanical thrombectomy</td>
</tr>
</tbody>
</table>

Additional Patient Care Considerations

In patients with AIS, evidence does not support the routine use of these diagnostic tests:

- Brain magnetic resonance imaging (MRI)
- Intracranial computerized tomographic angiography (CTA) and magnetic resonance angiography (MRA)
- Prolonged cardiac monitoring
- Echocardiography
- Blood cholesterol (if not on a statin)
- Obstructive sleep apnea
- Hyperhomocysteinemia
- Thrombophilic states
- Antiphospholipid antibodies

If AIS patients have atrial fibrillation, they should receive cardiac monitoring for at least the first 24 hours after AIS. Prolonged cardiac monitoring to detect atrial fibrillation after AIS may not be useful. For AIS patients who were already taking statins, it is reasonable to resume their medication while they are hospitalized. Measuring blood cholesterol of patients already on an optimized statin regimen may be useful to identify eligible candidates for PCSK9 inhibitor therapy, which may further reduce the risk of heart attack or stroke.

For AIS patients who are hospitalized, screening for dysphagia before the patient begins eating, drinking, or receiving oral medications to identify patients at increased risk for aspiration is reasonable. If the patients’ ability to eat is limited by dysphagia, healthcare providers should start tube feeding within 7 days.

References


To download the full version of the 2018 AIS Guideline, please visit http://stroke.ahajournals.org/lookup/doi/10.1161/STR.0000000000000158, or download a QR code reader app and scan this QR code with your smartphone.
Cold Feet?

PAD IS A RISK FACTOR FOR STROKE
LEARN TO RECOGNIZE THE SIGNS FOR PAD

Peripheral artery disease (PAD) affects more than 200 million adults worldwide and over 8.5 million in the United States. While it is a serious risk factor for coronary artery disease and cerebrovascular disease, PAD remains a largely overlooked condition. But together, we can change that.

Download your free copy of the PAD toolkit, designed specifically for healthcare professionals.

GETTING TO THE HEART OF VASCULAR HEALTH
heart.org/PADtoolkit

Aralez Pharmaceuticals is a proud sponsor of the American Heart Association’s efforts to educate patients about peripheral artery disease.
Session to highlight link between CVD brain health and cognitive decline

Speakers will discuss the relationship between cardiovascular brain health and cognitive decline in “Brain Health: A Cocktail for Healthy Aging” on Thursday at 1:30-3 p.m. in Room 151.

The session will also feature the recently published AHA/ASA Presidential Advisory “Defining Optimal Brain Health in Adults.”

The advisory complements the AHA’s Strategic Impact Goal to improve cardiovascular health of all Americans by 20 percent and to reduce deaths from cardiovascular diseases and stroke by 20 percent by the year 2020.

The role of cardiovascular risk factors in cerebrovascular injury is closely associated with cognitive impairment and decline. Because many cardiovascular risk factors are modifiable, it may be possible to maintain brain health and prevent dementia in later life.

With this link, the AHA is entering a new clinical, scientific and advocacy work space: brain health.

For many years, we thought about cognitive impairment and dementia as largely a neurodegenerative process that did not have anything to do with vascular risk factors and healthy lifestyle,” said Philip B. Gorelick, MD, MPH, FAHA, executive medical director of Mercy Health Hauenstein Neurosciences in Grand Rapids, Michigan, and chair of the advisory’s writing group.

“Alzheimer’s disease, the most common form of age-related cognitive impairment, has been the poster child of cognitively impairing diseases of later life. More recently, we have learned that vascular risk factors and lifestyle are linked to Alzheimer’s disease. Thus, Alzheimer’s disease may be preventable, or we may be able to slow down the process.”

The writing group employed the AHA’s Life’s Simple 7 to outline a strategy for maintaining brain health. Seven metrics that define optimal brain health in adults include four ideal health behaviors (nonsmoking, physical activities, healthy diet consistent with current guidelines and body mass index of <25 kg/m2) and three ideal health factors (untreated blood pressure of <120/<80 mm Hg, untreated cholesterol <200 mg/dL and fasting blood glucose <100 mg/dL).

“Achieving optimal cardiovascular health can have a dramatic impact on reducing the risk of heart attack, stroke and dementia,” said Lee H. Schwamm, MD, FAHA, professor of neurology at Harvard Medical School in Boston, Massachusetts.

“The audience will leave with a better understanding of why a broader definition of the impact of vascular disease on the brain is imperative, why brain health should be an important endpoint in trials studying interventions to reduce vascular events and how new strategies are needed to blunt that trajectory many decades upstream from when patients present with symptoms of cognitive decline.”

Speakers also will examine the scientific definitions of optimal brain health and the pathophysiologic mechanisms that link vascular and neuronal function.

Costantino Iadecola, MD, director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medical College in New York City, will weigh in on the vascular contributions to cognitive impairment and dementia. He also will explore the role of the neurovascular unit, which is the focal point for vascular injury. A tightly coupled, highly functioning neurovascular unit may prevent the downstream consequences from the metabolic and genetic dysfunction that leads to cognitive decline.

Maintaining optimal brain health and preventing or controlling vascular risk factors isn’t limited to the aging and elderly, Schwamm said. “We want to establish a platform for brain health in your 30s, which you can carry forward the rest of your life to enjoy your 70s and 80s. The longer you sustain a youthful brain, the longer you postpone cognitive decline and recognizable symptoms of brain injury.”

Speakers also will identify recommendations of the AHA’s Taskforce on Brain Health and Healthy Aging and the organization’s advocacy efforts.

DEBATES

continued from page 3

A comparison of direct aspiration versus stent retriever as a first approach

Subgroup Analyses of the DEFUSE 3 Study (LB6)
Marten G. Lansberg, Stanford University, Stanford, California

The Effect of Rivaroxaban With Aspirin on Stroke Outcomes in the Cardiovascular Outcomes for People Using Antithrombotic Strategies (COMPASS) Trial (LB7)
Mukul Sharma, McMaster University, Hamilton, Ontario, Canada

Ticagrelor With Aspirin on Platelet Reactivity in Minor Stroke or Transient Ischemic Attack (PRINCE Trial)-Final Analysis (LB8)
Yilong Wang, Beijing Tiantan Hospital, Beijing, China

Thrombectomy or Stent Retriever as a First Approach (COMPASS): A Randomized Trial (LB4)
J. Mocco, Mount Sinai Hospital, New York

Don’t miss these important late-breaking trial results at ISC today and Friday!

Thursday Main Event
10:30 a.m.-Noon
Thursday, Jan. 25
Hall K

• 11 a.m.
A Comparison of Direct Aspiration Versus Stent Retriever as a First Approach (COMPASS): A Randomized Trial (LB4)
J. Mocco, Mount Sinai Hospital, New York

• 11:12 a.m.
ARISE II Trial Results (LBS), Osama Zaidat, Mercy Health St. Vincent’s Hospital, Toledo, Ohio

• 11:24 a.m.
Subgroup Analyses of the DEFUSE 3 Study (LB6)
Marten G. Lansberg, Stanford University, Stanford, California

• 11:36 a.m.
The Effect of Rivaroxaban With Aspirin on Stroke Outcomes in the Cardiovascular Outcomes for People Using Antithrombotic Strategies (COMPASS) Trial (LB7)
Mukul Sharma, McMaster University, Hamilton, Ontario, Canada

• 11:48 a.m.
Ticagrelor With Aspirin on Platelet Reactivity in Minor Stroke or Transient Ischemic Attack (PRINCE Trial)-Final Analysis (LB8)
Yilong Wang, Beijing Tiantan Hospital, Beijing, China

Friday Closing Main Event
10:30 a.m.
Friday, Jan. 26
Hall K

• 11:53 a.m.
Pharyngeal Electrical Stimulation for Early Decannulation in Tracheotomised Stroke Patients With Dysphagia (PHAST-TRAC): A Randomized, Single-blind, Pivotal, Superiority Trial (LB16)
Philip M. Bath, University of Nottingham, Nottingham, United Kingdom

• 12:05 p.m.
DEFUSE 3 Angiographic Results Correlated With Clinical and Imaging Outcomes (LB17)
Michael P. Marks, Stanford Hospital, Stanford, California

• 12:17 p.m.
Final Results of the RHAPOSODY Trial
Patrick Lyden, Cedars-Sinai Medical Center, Los Angeles, California
Let’s transform the acute ischemic and cryptogenic stroke care continuum. Together.

medtronic.com/stroke


© 2017 Medtronic. All rights reserved. Medtronic, Medtronic RVE and Further Together are trademarks of a Medtronic company. DCC00076935
Rev A, Dec 2017, UC2018D6391EN

The Solitaire™ Revascularization Device is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA). Endovascular therapy with the device should be started within 6 hours of symptom onset.

The Solitaire™ Revascularization Device is indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment.

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician.
REDUCE STROKE RISK IN CRYPTOGENIC STROKE PATIENTS

Transform the standard of care with the world’s smallest, most accurate insertable cardiac monitor.¹

CRYSTAL AF STUDY

Reveal™ ICM: Superior to standard monitoring.²

Detection of Atrial Fibrillation by 36 months

<table>
<thead>
<tr>
<th>Hazard ratio</th>
<th>8.8 (95% CI, 3.5 - 22.2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P</td>
<td>&lt; 0.001 by log-rank test</td>
</tr>
</tbody>
</table>

Short- and intermediate-term cardiac monitoring may miss many patients with paroxysmal AF.²

The CRYSTAL-AF Study found that continuous monitoring with Reveal ICM is superior to standard monitoring for the detection of AF in cryptogenic stroke patients.

84 DAYS

median time to AF detection in cryptogenic stroke patients⁷

88%

of patients who had AF would have been missed if only monitored for 30 days⁸

Medtronic
9775 Toledo Way
Irvine, CA 92618
USA
Tel 877.526.7890
Fax 763.526.7888
medtronic.com

Brief Statement: REVEAL LINQ™ Linq11 Insertable Cardiac Monitor and Patient Assistant

INDICATIONS: REVEAL LINQ™ LINQ11 Insertable Cardiac Monitor: The REVEAL LINQ Insertable Cardiac Monitor is an implantable patient-activated and automatically-activated monitoring system that records subcutaneous ECG and is indicated in the following cases: patients with clinical syndromes or situations at increased risk of cardiac arrhythmias; patients who experience transient symptoms such as dizziness, palpitations, syncope, and chest pain that may suggest a cardiac arrhythmia. This device has not been specifically tested for pediatric use. Patient Assistant: The Patient Assistant is intended for unsupervised patient use away from a hospital or clinic. The Patient Assistant activates the data management feature in the Reveal Insertable Cardiac Monitor to initiate recording of cardiac event data in the implanted device memory. CONTRAINDICATIONS: There are no known contraindications for the implant of the Reveal LINQ Insertable Cardiac Monitor. However, the patient’s particular medical condition may dictate whether or not a subcutaneous, chronically implanted device can be tolerated. WARNINGS/PRECAUTIONS: REVEAL LINQ™ LINQ11 Insertable Cardiac Monitor: Patients with the Reveal LINQ Insertable Cardiac Monitor should avoid sources of diathermy, high sources of radiation, electrocautery, external defibrillation, lithotripsy, therapeutic ultrasound and radiofrequency ablation to avoid electrical reset of the device, and/or inappropriate sensing as described in the Medical Procedure and EM Precautions manual. MRI scans should be performed only in a specified MRI environment under specified conditions as described in the Reveal LINQ MRI Technical Manual. Patient Assistant: Operation of the Patient Assistant near sources of electromagnetic interference, such as cellular phones, computer monitors, etc., may adversely affect the performance of this device. POTENTIAL COMPLICATIONS: Potential complications include, but are not limited to, device rejection phenomena (including local tissue reaction), device migration, infection, and erosion through the skin. See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-338-2518 and/or consult Medtronic’s website at www.medtronic.com.

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician.
Researchers exploring interactions, mechanisms of stroke, diabetes

The effects of interactions between stroke and diabetes are clear — but the mechanisms aren’t, a presenter said in a seminar Wednesday at ISC.

“Diabetes triggers systemic inflammation, arterial stiffness and endothelial dysfunction that leads to atherosclerosis and stroke,” said Wuwei Feng, MD, MS, associate professor of neurology and director of the Post-stroke Spasticity Clinic at the Medical University of South Carolina. “By the time you diagnose diabetes, the risk for stroke is already elevated.”

Stroke and diabetes share multiple risk factors, including obesity, hypertension, hyperlipidemia, inactivity, smoking and poor dietary habits.

Diabetes is a recognized risk factor for stroke, particularly ischemic stroke. AHA/ASA guidelines for primary stroke prevention recommend blood pressure below 140/90 mmHg and statins for adults with diabetes. The organization also recommends diabetes screening following an initial stroke or TIA for secondary stroke prevention. In addition, the American Diabetes Association recommends glycemic control and cardiovascular risk factor management.

“We have quite a few options with both lifestyle modification and medication,” Feng said.

Hyperglycemia, the defining diagnostic feature of all diabetes types, is involved, but the mechanisms are not clear. There may also be a deleterious effect from the recurrent hyperglycemia that commonly occurs during diabetes treatment.

Ischemic stroke on its own increases inflammation in the brain as well as advanced glycation end products, reduced GABA release, increased oxidative stress, increased cell death and vascular changes.

Animal models show increased ischemic damage in the presence of diabetes.

Kunjan R. Dave, PhD, research associate professor of neurology at the University of Miami Miller School of Medicine, found that hypoglycemia increases glucose transporter levels in the brain, which increases intra-ischemic lactate levels. But the effects are unclear.

Hyperglycemia, the more prevalent state in diabetes, increases cerebral damage from stroke. Ischemia and reperfusion impair vascular endothelial growth factor, which reduces VEGF signaling and vascular function.

“The functional outcome of stroke is worsened in all models of diabetes even when there is no change in infarct size,” said Aadvive Ergul, MD, PhD, Regents Professor of Physiology at the Medical College of Georgia. “Both diabetes and stroke are vascular diseases and lack of vascular function is associated with poorer outcomes.”

Hyperglycemia is associated with worse outcomes in acute ischemic stroke, but it’s unclear how to treat hyperglycemia during stroke. The SHINE (Stroke Hyperglycemia Insulin Network Effort) trial may provide answers later this year.

“The trial will inform many of the questions we all have about hyperglycemia and stroke,” said Karen C. Johnston, MD, MSc, professor of neurology at the University of Virginia and principle investigator of SHINE.

Karen C. Johnston, MD, MSc, (left), and Kunjan R. Dave, PhD, were among the presenters sharing key study results at Wednesday’s session “Impact of Diabetes on Stroke: From Bench to Bedside.”

HYPERTENSION

continued from page 3

Focus on lifestyle modification, blood pressure management and treatment.

“We know the lower the blood pressure, the better,” said Lackland, who is also professor of neurology at Medical University of South Carolina. “But how we reach that lower blood pressure will probably differ, depending on the culture and availability of treatment.”

That’s the theme we will be addressing.” For example, in sub-Saharan Africa, affordable anti-hypertensive medication is scarce and blood pressure readings aren’t often measured. But in the United States, blood pressure readings are routine and inexpensive medication is prevalent.

More than 300 million people have hypertension caused by high dietary salt, according to the World Hypertension League. The World Health Organization recommends that adults consume less than 2,000 mg/sodium daily. Dietary guidelines indicate that the majority of American eating more sodium than they should — an average of more than 3,400 mg/day.

In the United States, 70 percent of sodium consumed comes from processed and restaurant foods. Only a small amount comes from the salt shaker, either during cooking at home or at the dinner table. Conversely, in China, where sodium intake ranges from about 2,491 mg to 4,377 mg per day, most excess sodium in the diet is derived from the soy sauce pervasively used in home cooking. Reducing sodium and thereby stroke risk in China will likely require a different strategy than in the United States, where convenience food plays a major role.

The session will also include:

• Implementation of Hypertension Control Strategies to Reduce Stroke Risks
• Janet Wright, director of Million Hearts, will discuss critical global considerations for blood pressure measurement and stroke prevention.

The forum is the first to bring hypertension specialists and stroke neurologists together to take a global stance on blood pressure regulation, stroke risk and international population health.

“It is a new frontier,” Lackland said.

To download the full version of the 2017 hypertension guidelines, visit http://professional.heart.org/hypertension.
GLOBAL
continued from page 1
inroads to reduce stroke risk factors and improve health outcomes. In China, for example, the government has begun supplying a soy sauce substitute that contains only 50 percent sodium chloride, which is helping to reduce population-wide hypertension. Similarly, the governments of Sri Lanka and Northern Ireland have begun employing WHO’s M Power Program, a tobacco-free initiative that is helping to reduce smoking.

“We all need to do our part to prevent stroke by going after the underlying causes and lobbying our government,” said presenter M. Patrice Lindsay, BScN, PhD, from Etobicoke, Ontario, Canada. “The incidence of stroke isn’t going to change unless we do something about it.”

Policies that yield the greatest population impact target individuals, industry and government and also focus on prevention and risk factors such as sodium reduction, physical inactivity, smoking and high blood pressure, Lindsay said.

“When every region in the world, blood pressure is No. 1.”

Brazil is an example of how government policies can improve hyperacute and acute care in low-resource settings to impact stroke incidence and mortality, said presenter Sheila Martins, MD, PhD, from Alegre, Brazil.

For 20 years, stroke had been the leading cause of death. And initially, stroke prevention wasn’t a priority for Brazil’s Ministry of Health (MOH). “They argued that tPA was too expensive for Brazil’s universal and free health system,” Martins said. Yet, with stroke responsible for 400,000 deaths per year, the MOH came around.

Starting in 2008, the MOH launched several initiatives, including the Stroke Pilot Project, the Brazilian Stroke Network to improve stroke education and the National Policy for Stroke. Seventeen years after the FDA approved tPA use in the United States, it was approved to treat stroke in Brazil.

Because of these government programs and the development of 150 public and private stroke centers, stroke is now the second-leading cause of death in Brazil. “Involving the government to create a national stroke program in LMICs can be done,” Martins said.

Foad Adb Allah, MD, from Cairo, Egypt, wrapped up the session with a discussion about a proven strategy for improving the quality of life for stroke survivors in LMICs: home-based stroke rehabilitation, guided by tele-rehabilitation or DVD. “Home-based rehabilitation is feasible and a cost-effective measure for stroke recovery, and an option that’s available to LMICs,” Allah said.

SC 2018 offers two types of poster sessions: professor-led poster tours and one-on-one individual Q&A poster presentations.

Choose from 10 Professor-Led Poster Tours today at 5:15 p.m.-6:15 p.m. in Hall H. Expert moderators will lead these tours, which are organized by category; they provide a short presentation and Q&A with each of the poster authors in that section.

To take part, simply review the Poster Abstracts section of the Final Program (page 87) or view the Moderated Poster Sessions on the Mobile Meeting Guide app. Decide which section/category of posters you would like to attend. Then, at 5:10 p.m., arrive at the corresponding numbered “Section” sign for your selected section/category. Headsets will be available for ease of listening to the presenters.

During the Regular Poster Sessions, presenters will be at their posters for informal Q&As with attendees today at 6:15-6:45 p.m. in Hall H. These one-on-one posters are not a part of the earlier Professor-Led Poster Tours. To see the posters featured in today’s Regular Poster Sessions, go to page 94 of the Poster Abstracts section of the Final Program or view the Poster Sessions on the Mobile Meeting Guide app.

Posters also will be available for viewing in the Poster Hall (Hall H) today at 8 a.m.-6:45 p.m.

---

**Professor-Led Poster Tours**

5:15-6:15 p.m.
Posters TMP1–TMP120

1. Acute Endovascular Treatment Moderated Poster Tour II
2. Acute Nonendovascular Treatment Moderated Poster Tour
3. Basic and Preclinical Neuroscience of Stroke Recovery Moderated Poster Tour
4. Clinical Rehabilitation and Recovery Moderated Poster Tour
5. Community/Risk Factors Moderated Poster Tour II
6. Emergency Care/Systems Moderated Poster Tour
7. Health Services, Quality Improvement and Patient-Centered Outcomes Moderated Poster Tour II
8. In-hospital Treatment & Vascular Cognitive Impairment Moderated Poster Tour
9. Pediatric Stroke, Vascular Biology in Health and Disease and Vascular Malformations Moderated Poster Tour
10. Preventive Strategies Moderated Poster Tour

**Regular Poster Sessions**

6:15-6:45 p.m.
Posters TP1–TP428

These posters are not included in the 5:15 p.m. Professor-Led Poster Tour Session.

- Acute Endovascular Treatment Posters II
- Acute Neuroimaging Posters II
- Acute Nonendovascular Treatment Posters II
- Aneurysm Posters II
- Basic and Preclinical Neuroscience of Stroke Recovery Posters II
- Cerebral Large Artery Disease Posters II
- Clinical Rehabilitation and Recovery Posters II
- Community/Risk Factors Posters II
- Diagnosis of Stroke Etiology Posters II
- Emergency Care/Systems Posters II
- Experimental Mechanisms and Models Posters II
- Health Services, Quality Improvement, and Patient-Centered Outcomes Posters II
- In-hospital Treatment Posters II
- Intracerebral Hemorrhage Posters II
- Nursing Posters II
- Preventive Strategies Posters II
- SAH and Other Neurocritical Management Posters II
- Vascular Biology in Health and Disease Posters II
- Vascular Cognitive Impairment Posters II
- Ongoing Clinical Trials Posters II

---

**Did you know the AHA Patient Support Network has over 100,000 members?**

Help us grow the VTE community by sharing this resource with your DVT/PE patients.

Heart.org/SupportNetwork
Visit the Science & Technology Hall to extend your clinical and professional education with interactive learning, new products and services, and networking opportunities.

Showcasing more than 90 companies Wednesday and Thursday from 10 a.m. - 5 p.m., the hall lets you investigate diagnostic and monitoring equipment, clinical reporting and support services, new technology, staffing support services, education and more.

Also, stop by the American Heart Association/American Stroke Association’s HeadQuarters in Booth 445 to learn more about AHA/ASA initiatives, education, membership and publications.
Simulation Zone

The Simulation Zone (Booth 159) features two interactive displays:

- **Body Interact**: A 3-D immersive training platform that virtualizes acute and chronic neurovascular disorders.
- **The Mentice VIST® GS Simulator** is a portable high-fidelity endovascular simulator enabling hands-on procedural training for clinicians and medical professionals.

**Schedule**

**Thursday, Jan. 25**

**Body Interact Sessions:**
- Noon | 1 p.m. | 2 p.m.

**Mentice Sessions:**
- 12:30 p.m. | 1:30 p.m. | 2:30 p.m.

See the ISC 2018 Mobile Meeting Guide app or the online ISC 2018 Program Planner for more information about the sessions.

Expert Theater Schedule

**Booth 401**

Enjoy complimentary lunch* while learning the latest advances in stroke practices, services and technologies.

**Thursday, Jan. 25**

**12:10-12:40 p.m.**
- Cryptogenic Stroke — The Missing Link — Presenter: Robert Felberg, MD, medical director of the Overlook Hospital in Summit, New Jersey
- Supported by Medtronic

* Provided to attendees by the AHA/ASA. These events are not part of the official ISC 2018 as planned by the AHA Committee on International Stroke Programming.

Are You an AHA Member?

Renew or join as a professional member today to make a difference. You can effect change and reduce the global burden of cardiovascular disease and stroke through collaboration and knowledge transfer with other clinicians, scientists and health-care professionals.

https://professional.heart.org/professional

HeadQuarters Theater Schedule

**Thursday, Jan. 25**

**10:15-10:45 a.m.**
- Acute Stroke QI Project in China
  - Presenter: Louise Morgan, director of International Quality Improvement

**11-11:30 a.m.**
- Developments in Mission: Lifeline Stroke
  - Presenter: Peter Panagos and James Lugtu

Expert Theater

The Expert Theater offers targeted educational programs and features products and therapeutic treatments from industry supporters.

Poster Hall

Be sure to visit the Poster Hall, located adjacent to the Science & Technology Hall in Hall H, to see more than 500 posters each day.
Kernan said the effects of pioglitazone on stroke alone are also very positive. The original IRIS results, published in 2016, showed a non-significant reduction in stroke occurrence. A secondary analysis using current AHA stroke definitions showing significant secondary prevention effects will be presented during an oral presentation at 7:7:36 a.m. Thursday in 515 A.

The need for effective stroke prevention is significant, particularly for diabetes. “Cardiometabolic risk factors — hyperlipidemia, excessive weight, physical inactivity, hyperglycemia, tobacco use and hypertension are the top six leading causes of death in the world,” said Nathan Wong, PhD, professor and director of the Heart Disease Prevention Program at the University of California, Irvine. “The risk of ischemic stroke more than doubles in the setting of diabetes.”

Insulin resistance is among the hallmarks of both Type 1 and Type 2 diabetes. And while insulin resistance is just one of several deleterious effects of diabetes, it produces a variety of pro-atherosclerotic and pro-hypercoagulability changes: endothelial dysfunction, inflammation, dyslipidemia, proliferation of vascular smooth muscle cells and thrombosis. The culprits are familiar to a stroke specialist: hypertension, hyperlipidemia, and, most importantly, obesity.

Obesity is not just an excessive accumulation of adipose tissue, said Dawn Kleindorfer, MD, professor of neurology and vascular neurology at the University of Cincinnati. Adipose tissue is an endocrine organ.

Enlargement and inflammation of adipose tissue induce a change in its hormonal secretion profile. Changes in leptin production affect energy homeostasis. Increasing production of Interleukin 6 and TNF-α reduces insulin sensitivity and increases insulin resistance and systemic inflammatory responses. Secretion of procoagulants and PAI (plasminogen activator inhibitor)-1 increases thrombosis and fibrinolysis.

“One gets you seven,” Kleindorfer said. “Every one-unit increase in BMI above 20 kg/m² increases stroke risk by 7 percent.” Stroke also increases the risk of diabetes. The incidence of diabetes is significantly higher after stroke and after other cardio-vascular diseases, said Joshua Z. Willey, MD, MS, assistant professor of neurology at Columbia University Medical Center. Stroke patients who develop diabetes are at increased risk of recurrent stroke. Diabetes also increases the risk of death and worsening disability and cognition.

“Every patient with a stroke should be screened for diabetes,” Willey said. “For patients with stroke, their risk for diabetes goes far beyond what you might expect for age and ethnicity alone.”

Claim Your CME/CE Credit
You have two ways to complete your conference evaluation and claim your CME/CE credits for the conference, pre-conference symposia and/or nursing symposium.
1. Stop by the Communication Center at Registration in front of Hall H, Level 1, in the Los Angeles Convention Center.
2. Visit learn.heart.org from any computer with an Internet connection. CME/CE credit will no longer be available to claim for ISC 2018 after July 26, 2018.

International attendees may obtain an attendance verification form at one of the self-service terminals in Registration, located in the front of Hall H, Level 1.
Patients admitted directly to endovascular-capable centers have significantly higher rates of functional independence at 90 days (60.0% vs. 52.2%, p=0.02) than transfer patients who received endovascular therapy due to reduced delays to treatment.  

60% mRS 0-2
VS. 52.2%, p=0.02
HIGHER RATES OF FUNCTIONAL INDEPENDENCE AT 90 DAYS WITH DIRECT ADMISSION

Patients admitted directly to endovascular-capable centers have significantly higher rates of functional independence at 90 days (60.0% vs. 52.2%, p=0.02) than transfer patients who received endovascular therapy due to reduced delays to treatment.  

61.8% mRS 0-2
VS. 50.2%, p=0.002
HIGHER RATES OF FUNCTIONAL INDEPENDENCE AT 90 DAYS WITH BGC

Patients admitted directly to endovascular-capable centers have significantly higher rates of functional independence at 90 days (61.8% vs. 50.2%, p=0.002) with fewer passes (1.7 vs. 2.0, p=0.0008).

Stratis is one of the largest Acute Ischemic Stroke studies published to date.

Stoke September 2017.

1 STRATIS Registry cases were performed using 97% Solitaire™ device (Includes Solitaire™ 2 and Solitaire™ Platinum) and 3% Medtronic™ Capture LP revascularization device as first device.

FEWER PASSES WITH BALLOON GUIDE CATHETER

Solitaire™ device + BGC vs. Solitaire™ device + Distal Access Catheter result in higher rates of functional independence at 90 days (61.8% vs. 50.2%, p=0.0002) with fewer passes (1.7 vs. 2.0, p=0.0008).

© 2017 Medtronic All rights reserved. Medtronic, Medtronic logo and Further are trademarks of Medtronic. All other brands are trademarks of Medtronic company. DC00076759 Rev A, Dec 2017

Medtronic
9775 Toledo Way
Irvine, CA 92618
USA
Tel 877.526.7890
Fax 763.526.7888
medtronic.com
Interactive Collections of Freely Available Articles from AHA/ASA Journals

DOWNLOAD THE BLIPPAR APP
App required for free, full-text access to Trend Watch.

AVAILABLE ON

VISIT AHA/ASA HEADQUARTERS, BOOTH #445, TO PICK UP YOUR COPY.
You can also access the issue at www.ahajournals.org/content/trend-watch